Aytu BioScience Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.62
- Today's High:
- $1.7048
- Open Price:
- $1.6507
- 52W Low:
- $1.4
- 52W High:
- $16.194
- Prev. Close:
- $1.69
- Volume:
- 9634
Company Statistics
- Market Cap.:
- $6.35 million
- Book Value:
- 10.825
- Revenue TTM:
- $104.12 million
- Operating Margin TTM:
- -21.36%
- Gross Profit TTM:
- $52.28 million
- Profit Margin:
- -30.81%
- Return on Assets TTM:
- -8.8%
- Return on Equity TTM:
- -62.86%
Company Profile
Aytu BioScience Inc had its IPO on 2017-02-01 under the ticker symbol AYTU.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Aytu BioScience Inc has a staff strength of 164 employees.
Stock update
Shares of Aytu BioScience Inc opened at $1.65 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.62 - $1.7, and closed at $1.62.
This is a -4.14% slip from the previous day's closing price.
A total volume of 9,634 shares were traded at the close of the day’s session.
In the last one week, shares of Aytu BioScience Inc have slipped by -5.26%.
Aytu BioScience Inc's Key Ratios
Aytu BioScience Inc has a market cap of $6.35 million, indicating a price to book ratio of 0.2432 and a price to sales ratio of 0.1298.
In the last 12-months Aytu BioScience Inc’s revenue was $104.12 million with a gross profit of $52.28 million and an EBITDA of $-13218000. The EBITDA ratio measures Aytu BioScience Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aytu BioScience Inc’s operating margin was -21.36% while its return on assets stood at -8.8% with a return of equity of -62.86%.
In Q1, Aytu BioScience Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 6.1%.
Aytu BioScience Inc’s PE and PEG Ratio
- Forward PE
- 10.6952
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-11.78 per share while it has a forward price to earnings multiple of 10.6952 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aytu BioScience Inc’s profitability.
Aytu BioScience Inc stock is trading at a EV to sales ratio of 0.1159 and a EV to EBITDA ratio of -0.6054. Its price to sales ratio in the trailing 12-months stood at 0.1298.
Aytu BioScience Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $147.22 million
- Total Liabilities
- $85.42 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Aytu BioScience Inc ended 2024 with $147.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $147.22 million while shareholder equity stood at $40.91 million.
Aytu BioScience Inc ended 2024 with $0 in deferred long-term liabilities, $85.42 million in other current liabilities, in common stock, $-301672000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $19.18 million and cash and short-term investments were $19.18 million. The company’s total short-term debt was $13,708,000 while long-term debt stood at $11.39 million.
Aytu BioScience Inc’s total current assets stands at $78.47 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $34.04 million compared to accounts payable of $14.67 million and inventory worth $13.64 million.
In 2024, Aytu BioScience Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Aytu BioScience Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.62
- 52-Week High
- $16.194
- 52-Week Low
- $1.4
- Analyst Target Price
- $70
Aytu BioScience Inc stock is currently trading at $1.62 per share. It touched a 52-week high of $16.194 and a 52-week low of $16.194. Analysts tracking the stock have a 12-month average target price of $70.
Its 50-day moving average was $1.74 and 200-day moving average was $2.48 The short ratio stood at 4.21 indicating a short percent outstanding of 0%.
Around 419.6% of the company’s stock are held by insiders while 1191.8% are held by institutions.
Frequently Asked Questions About Aytu BioScience Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers. The Consumer Health segment, which consists of various consumer health products sell directly to consumers. It also offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. In addition, the company provides Karbinal ER, for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.